ABOUT
Our Members
Board of Directors
Staff
Sponsors
Contact Us
Issue Areas
COVID-19
Reducing Health Costs
Health Care Reform
Value
Real-World Evidence
Patient Engagement
Personalized Health
FDA Regulations
Resources
Member Resources
Meetings & Events
Newsroom
Letters & Comments
Job Bank
Education
Health Care Quality
Value Classroom
Patient-Focused Medical Product Development Series
Webinars
Blog
Membership
Our Members
Standards of Excellence
Join Us
Toggle navigation
letters & comments
NHC Comments on ICER Unsupported Price Increase Assessment
02/13/2019
Read More
NHC Comments on Framework for a Real-World Evidence Program; Availability
02/07/2019
Read More
NHC Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses
01/25/2019
Read More
NHC Comments on Patient Engagement in Medical Device Clinical Trials Discussion Document
01/08/2019
Read More
NHC Comments on Advance Notice of Proposed Rulemaking: International Price Index Model for Medicare Part B Drugs
12/31/2018
Read More
NHC Letter on State Relief and Empowerment Waivers
12/24/2018
Read More
NHC Comments on Patient-Focused Drug Development Guidance: Methods To Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments
12/14/2018
Read More
NHC Comments on Accountable Care Organizations Pathways to Success
10/16/2018
Read More
NHC Comments on FDA Standard Core Clinical Outcome Assessments and Endpoints
10/15/2018
Read More
« Previous
1
2
3
4
5
6
Next »
